Tracking trends in the Top End: clindamycin and erythromycin resistance in Group A Streptococcus in the Northern Territory, 2012–2023
DOI:
https://doi.org/10.33321/cdi.2024.48.31Keywords:
group A streptococcus, Streptococcus pyogenes, clindamycin, erythromycin, antibiotic resistance, Northern TerritoryAbstract
This retrospective study reviewed the macrolide resistance rates of Group A Streptococcus (GAS) isolates in the Northern Territory from 2012 to 2023. Clindamycin and erythromycin resistance rates peaked in 2021, at 6.0% and 12.2% respectively, and then returned to near baseline at 1–2% in 2023. Increased resistance rates were identified in the Top End of Australia from mid-2020, followed 15 months later by high rates in central Australia in 2022. Factors associated with resistant isolates were living in a rural region and of age 18 years and older. Possible explanations include a transient clonal introduction of a resistant GAS strain to the Northern Territory from 2020 to 2022. Ongoing surveillance is required to monitor regional trends and identify temporal variations in resistant isolates.
Downloads
References
Birrell JM, Boyd R, Currie BJ, Anstey NM, Abeyaratne A, Majoni SW et al. Invasive group A streptococcal disease in the Northern Territory and the impact of melioidosis antibiotic prophylaxis. Med J Aust. 2022;217(10):544–5. doi: https://doi.org/10.5694/mja2.51739.
White BP, Siegrist EA. Increasing clindamycin resistance in group A streptococcus. Lancet Infect Dis. 2021;21(9):1208–9. doi: https://doi.org/10.1016/S1473-3099(21)00456-4.
Cortés-Penfield N, Ryder JH. Should linezolid replace clindamycin as the adjunctive antimicrobial of choice in group A streptococcal necrotizing soft tissue infection and toxic shock syndrome? A focused debate. Clin Infect Dis. 2023;76(2):346–50. doi: https://doi.org/10.1093/cid/ciac720.
Bowen AC, Mahé A, Hay RJ, Andrews RM, Steer AC, Tong SY et al. The global epidemiology of impetigo: a systematic review of the population prevalence of impetigo and pyoderma. PLoS One. 2015;10(8):e0136789. doi: https://doi.org/10.1371/journal.pone.0136789.
Yu D, Guo D, Zheng Y, Yang Y. A review of penicillin binding protein and group A Streptococcus with reduced-β-lactam susceptibility. Front Cell Infect Microbiol. 2023;13:1117160. doi: https://doi.org/10.3389/fcimb.2023.1117160.
Fay K. Onukwube J, Chochua S, Schaffner W, Ciesak P, Lynfield R et al. Patterns of antibiotic nonsusceptibility among invasive group A Streptococcus infections – United States, 2006–2017. Clin Infect Dis. 2021;73(11):1957–64. doi: https://doi.org/10.1093/cid/ciab575.
Li Y, Rivers J, Mathis S, Li Z, McGee L, Chochua S et al. Continued increase of erythromycin nonsusceptibility and clindamycin nonsusceptibility among invasive group A streptococci driven by genomic clusters, United States, 2018–2019. Clin Infect Dis. 2023;76(3):e1266–9. doi: https://doi.org/10.1093/cid/ciac468.
Pesola AK, Sihvonen R, Lindholm L, Pätäri-Sampo A. Clindamycin resistant emm33 Streptococcus pyogenes emerged among invasive infections in Helsinki metropolitan area, Finland, 2012 to 2013. Euro Surveill. 2015;20(18):21117. doi: https://doi.org/10.2807/1560-7917.es2015.20.18.21117.
Powell LM, Choi SJ, Chipman CE, Grund ME, LaSala PR, Lukomski S. Emergence of erythromycin-resistant invasive group A Streptococcus, West Virginia, USA, 2020–2021. Emerg Infect Dis. 2023;29(5):898–908. doi: https://doi.org/10.3201/eid2905.221421.
Meletis G, Soulopoulos Ketikidis AL, Floropoulou N, Tychala A, Kagkalou G, Vasilaki O et al. Antimicrobial resistance rates of Streptococcus pyogenes in a Greek tertiary care hospital: 6-year data and literature review. New Microbiol. 2023;46(1):37–42.
Villalón P, Bárcena M, Medina-Pascual MJ, Garrido N, Pino-Rosa S, Carrasco G et al. National surveillance of tetracycline, erythromycin, and clindamycin resistance in invasive Streptococcus pyogenes: a retrospective study of the situation in Spain, 2007–2020. Antibiotics (Basel). 2023;12(1):99. doi: https://doi.org/10.3390/antibiotics12010099.
Hua CZ, Yu H, Xu HM, Yang LH, Lin AW, Lyu Q et al. A multi-center clinical investigation on invasive Streptococcus pyogenes infection in China, 2010–2017. BMC Pediatr. 2019;19(1):181. doi: https://doi.org/10.1186/s12887-019-1536-1.
Australian Bureau of Statistics. Snapshot of Northern Territory: high level summary data for Northern Territory in 2021. [Webpage.] Canberra: Australian Bureau of Statistics; 28 June 2022. Available from: https://www.abs.gov.au/articles/snapshot-nt-2021.
Spízek J, Rezanka T. Lincomycin, clindamycin and their applications. Appl. Microbiol. Biotechnol. 2004;64(4):455–64. doi: https://doi.org/10.1007/s00253-003-1545-7.
Johnson AF, LaRock CN. Antibiotic treatment, mechanisms for failure, and adjunctive therapies for infections by group A streptococcus. Front Microbiol. 2021;12:760255. doi: https://doi.org/10.3389/fmicb.2021.760255.
Holt D, Giffard P. Staphylococcus aureus and Streptococcus pyogenes in the north: distinctively different. Microbiol Aust. 2022;43(3):104–7. doi: https://doi.org/10.1071/MA22034.
Giffard PM, Tong SYC, Holt DC, Ralph AP, Currie BJ. Concerns for efficacy of a 30-valent M-protein-based Streptococcus pyogenes vaccine in regions with high rates of rheumatic heart disease. PLoS Negl Trop Dis. 2019;13(7):e0007511. doi: https://doi.org/10.1371/journal.pntd.0007511.
Meumann EM, Krause VL, Baird R, Currie BJ. Using genomics to understand the epidemiology of infectious diseases in the Northern Territory of Australia. Trop Med Infect Dis. 2022;7(8):181. doi: https://doi.org/10.3390/tropicalmed7080181.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
